SI2326650T1 - Dihidropiridoftalazinonski inhibitorji poli(ADP-riboza)polimeraze (PARP) - Google Patents

Dihidropiridoftalazinonski inhibitorji poli(ADP-riboza)polimeraze (PARP)

Info

Publication number
SI2326650T1
SI2326650T1 SI200930881T SI200930881T SI2326650T1 SI 2326650 T1 SI2326650 T1 SI 2326650T1 SI 200930881 T SI200930881 T SI 200930881T SI 200930881 T SI200930881 T SI 200930881T SI 2326650 T1 SI2326650 T1 SI 2326650T1
Authority
SI
Slovenia
Prior art keywords
parp
adp
ribose
polymerase
poly
Prior art date
Application number
SI200930881T
Other languages
English (en)
Slovenian (sl)
Inventor
Bing Wang
Daniel Chu
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of SI2326650T1 publication Critical patent/SI2326650T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
SI200930881T 2008-08-06 2009-07-27 Dihidropiridoftalazinonski inhibitorji poli(ADP-riboza)polimeraze (PARP) SI2326650T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US15103609P 2009-02-09 2009-02-09
US17308809P 2009-04-27 2009-04-27
EP09805360.6A EP2326650B9 (en) 2008-08-06 2009-07-27 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
PCT/US2009/051879 WO2010017055A2 (en) 2008-08-06 2009-07-27 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)

Publications (1)

Publication Number Publication Date
SI2326650T1 true SI2326650T1 (sl) 2014-04-30

Family

ID=41129519

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200930881T SI2326650T1 (sl) 2008-08-06 2009-07-27 Dihidropiridoftalazinonski inhibitorji poli(ADP-riboza)polimeraze (PARP)
SI200931668T SI2767537T1 (sl) 2008-08-06 2009-07-27 Dihidropiridoftalazinonski inhibitorji poli(adp-riboza) polimeraze (parp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931668T SI2767537T1 (sl) 2008-08-06 2009-07-27 Dihidropiridoftalazinonski inhibitorji poli(adp-riboza) polimeraze (parp)

Country Status (31)

Country Link
US (7) US8012976B2 (https=)
EP (3) EP2326650B9 (https=)
JP (3) JP5984389B2 (https=)
KR (1) KR101846029B1 (https=)
CN (3) CN104478875B (https=)
AR (1) AR072970A1 (https=)
AU (1) AU2009279944B2 (https=)
BR (1) BRPI0917119B1 (https=)
CA (1) CA2732797C (https=)
CY (3) CY1115022T1 (https=)
DK (2) DK2767537T3 (https=)
ES (2) ES2625817T3 (https=)
FR (1) FR19C1071I2 (https=)
GB (1) GB2462361A (https=)
HR (1) HRP20170982T1 (https=)
HU (2) HUE035295T2 (https=)
IL (1) IL211070A (https=)
LT (2) LT2767537T (https=)
LU (1) LUC00140I2 (https=)
MX (1) MX2011001328A (https=)
NL (1) NL301021I2 (https=)
NO (1) NO2019042I1 (https=)
NZ (1) NZ591166A (https=)
PL (2) PL2767537T3 (https=)
PT (2) PT2326650E (https=)
SG (2) SG193842A1 (https=)
SI (2) SI2326650T1 (https=)
SM (1) SMT201700312T1 (https=)
TW (2) TWI448464B (https=)
WO (1) WO2010017055A2 (https=)
ZA (1) ZA201100897B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
EP2531033A4 (en) * 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
KR20190120458A (ko) * 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
CN106496173A (zh) * 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
MX353578B (es) 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
MX2014008071A (es) * 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
EP2804602B1 (en) 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN105916846A (zh) * 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
CN110650961B (zh) * 2017-05-08 2022-09-27 广州丹康医药生物有限公司 Parp抑制剂、其药物组合物、制备方法和应用
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3078806A1 (en) 2017-10-13 2019-04-18 Merck Patent Gmbh Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
JP7370032B2 (ja) 2019-05-14 2023-10-27 スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
EP4118105A2 (en) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc fusion protein and uses thereof
US20230414522A1 (en) 2020-11-13 2023-12-28 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
EP4256088A1 (en) 2020-12-07 2023-10-11 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
WO2022200982A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP4319755A4 (en) 2021-04-08 2025-03-26 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of parp activity
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
JP2025523385A (ja) * 2022-06-08 2025-07-23 バロ ヘルス，インコーポレイテッド 三環性フタラジノンｐａｒｐ阻害剤及び使用方法
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
JP2025531798A (ja) * 2022-09-09 2025-09-25 上海▲瑛▼黎薬業有限公司 含窒素複素環化合物、その医薬組成物および使用
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN116283924B (zh) * 2023-01-16 2024-07-26 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
ATE198623T1 (de) 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2003211381B9 (en) 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JPWO2004043959A1 (ja) * 2002-11-12 2006-03-09 持田製薬株式会社 新規ｐａｒｐ阻害剤
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
WO2005080356A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
WO2009024190A1 (en) 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
ES2504690T3 (es) * 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
WO2009099736A2 (en) 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
CN104478875B (zh) 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
KR20110053424A (ko) 2008-08-12 2011-05-23 베링거 인겔하임 인터내셔날 게엠베하 사이클로알킬-치환된 피페라진 화합물의 제조 방법
EP2531033A4 (en) 2010-02-03 2013-07-31 Biomarin Pharm Inc POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
KR20190120458A (ko) 2010-10-21 2019-10-23 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN105916846A (zh) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 用于合成经保护的n-烷基三唑甲醛的三唑中间体
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Also Published As

Publication number Publication date
CY1119218T1 (el) 2018-02-14
CY2019044I2 (el) 2024-02-16
CN103896942A (zh) 2014-07-02
HK1157755A1 (en) 2012-07-06
EP2326650B1 (en) 2014-02-26
DK2326650T3 (en) 2014-03-10
EP2326650A4 (en) 2012-03-21
GB2462361A (en) 2010-02-10
LTPA2019522I1 (lt) 2019-12-27
RU2514937C2 (ru) 2014-05-10
US10543209B2 (en) 2020-01-28
US20110237581A1 (en) 2011-09-29
SG10201809895YA (en) 2018-12-28
CN102171214B (zh) 2015-06-24
EP3241832A1 (en) 2017-11-08
CN104478875A (zh) 2015-04-01
US8999987B2 (en) 2015-04-07
NZ591166A (en) 2012-11-30
BRPI0917119B1 (pt) 2021-07-13
US20130190306A1 (en) 2013-07-25
US8012976B2 (en) 2011-09-06
LT2767537T (lt) 2017-08-10
WO2010017055A2 (en) 2010-02-11
AU2009279944A1 (en) 2010-02-11
ES2466565T3 (es) 2014-06-10
US20210069191A1 (en) 2021-03-11
HRP20170982T1 (hr) 2017-09-22
ZA201100897B (en) 2012-06-27
LTC2767537I2 (lt) 2020-11-10
PT2767537T (pt) 2017-07-17
JP2011530513A (ja) 2011-12-22
LUC00140I2 (https=) 2021-02-12
US20180117045A1 (en) 2018-05-03
PL2767537T3 (pl) 2017-09-29
SMT201700312T1 (it) 2017-09-07
US10780088B2 (en) 2020-09-22
GB0913474D0 (en) 2009-09-16
CA2732797C (en) 2017-01-03
MX2011001328A (es) 2011-04-04
RU2011108493A (ru) 2012-09-20
NO2019042I1 (no) 2019-11-28
BRPI0917119A2 (pt) 2015-11-17
LUC00140I1 (https=) 2019-12-13
CY2019044I1 (el) 2020-05-29
CN104478875B (zh) 2017-04-12
EP2326650A2 (en) 2011-06-01
IL211070A (en) 2014-11-30
AU2009279944B2 (en) 2014-09-11
FR19C1071I1 (https=) 2020-01-17
JP2015157843A (ja) 2015-09-03
TW201018688A (en) 2010-05-16
ES2625817T3 (es) 2017-07-20
SG193842A1 (en) 2013-10-30
KR101846029B1 (ko) 2018-04-06
KR20110040973A (ko) 2011-04-20
NL301021I1 (nl) 2019-12-18
HUE035295T2 (en) 2018-05-02
EP2767537A1 (en) 2014-08-20
JP2018012698A (ja) 2018-01-25
HK1200813A1 (en) 2015-08-14
EP2326650B9 (en) 2014-09-10
CA2732797A1 (en) 2010-02-11
US20100035883A1 (en) 2010-02-11
NL301021I2 (nl) 2020-04-14
EP2767537B1 (en) 2017-04-12
TW201422617A (zh) 2014-06-16
FR19C1071I2 (fr) 2020-10-16
JP5984389B2 (ja) 2016-09-06
PT2326650E (pt) 2014-05-06
SI2767537T1 (sl) 2017-08-31
PL2326650T3 (pl) 2014-07-31
US20200261454A1 (en) 2020-08-20
HUS1900053I1 (hu) 2020-02-28
US8420650B2 (en) 2013-04-16
US9820985B2 (en) 2017-11-21
US20150209357A1 (en) 2015-07-30
CY1115022T1 (el) 2016-12-14
US11364241B2 (en) 2022-06-21
CN102171214A (zh) 2011-08-31
AR072970A1 (es) 2010-10-06
DK2767537T3 (da) 2017-06-19
IL211070A0 (en) 2011-04-28
WO2010017055A3 (en) 2010-05-27
TWI448464B (zh) 2014-08-11

Similar Documents

Publication Publication Date Title
HRP20170982T1 (hr) Dihidropiridoftalazinonski inhibitori poli(adp-ribozne)polimeraze (parp)
IL213993A0 (en) Poly (adp-ribose) polymerase (parp) inhibitors
HUS1800022I1 (hu) Amid-szubsztituált indazol-származékok mint poli(ADP-ribóz)-polimeráz (PARP) inhibitorok
SG2014013411A (en) Inhibitors of poly(adp-ribose)polymerase
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
IL209932A0 (en) Cyclopropyl polymerase inhibitors
ZA200903996B (en) Inhibitors of poly (adp-ribose)polymerase
HK1163687A (en) Poly (adp-ribose) polymerase (parp) inhibitors
HK1139935A (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) activity
GB0806920D0 (en) Polymerase inhibitors
GB0806914D0 (en) Polymerase inhibitors
GB0806917D0 (en) Polymerase inhibitors
GB0806915D0 (en) Polymerase inhibitors
GB0806911D0 (en) Polymerase inhibitors
GB0806912D0 (en) Polymerase inhibitors
GB0806919D0 (en) Polymerase inhibitors
GB0806913D0 (en) Polymerase inhibitors